danshen
Botanicalexperimental
Clinical trial activity
17 trials · 28 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
2
Phase 4
6
Earliest trial started Jan 1, 2006 (NCT01033630)
Timeline
Indications
Approved for
Studied for
- Altitude Sickness · Phase 1/Phase 2
- Cardiovascular Diseases · Phase 2/Phase 3
- Colitis, Ulcerative · Early Phase 1
- Coronary Disease · Phase 4
- Dementia, Vascular · Phase 2
- Diabetic Retinopathy · Phase 3
- Diarrhea · Early Phase 1
- Drugs, Investigational · Phase 2/Phase 3
- Dysmenorrhea · Phase 2
- Hypertension · Phase 2
- Hypertension, Pulmonary · Phase 2/Phase 3
- Lung Diseases · Phase 2/Phase 3
- Medicine, Chinese Traditional · Early Phase 1
- Microvascular Angina · Phase 4
- Myocardial Infarction · Phase 4
- Neurocirculatory Asthenia · Phase 4
- Pulmonary Arterial Hypertension · Phase 2/Phase 3
- Purpura · Phase 1/Phase 2
- Ventricular Remodeling · Phase 4
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- danshen-201
- danshen dripping pills
- danshen-gegen
- danshen jiang fu
- ds-201
- fufangdanshen
- phenanthro(1,2-b)furan-2-sulfonic acid, 6,7,8,9,10,11-hexahydro-1,6,6-trimethyl-10,11-dioxo-, sodium salt
- shandong danshen-jiang-fu
- sichuan danshen-jiang-fu
- sodium tanshinone ii a sulfonate
- sodium tanshinone iia sulfonate
- sodium tanshinone iia sulfonate
- sodium tanshinone iia sulfonate
- tanshinone ii a sodium sulfonate
- tanshinone iia sulfonate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07041359 | Phase 4 | Aug 18, 2025 | Chinese Academy of Medical Sciences |
| NCT06727890 | Phase 4 | Jan 1, 2025 | Shandong University |
| NCT05295329 | N/A | Apr 1, 2022 | Jiao Tong University |
| NCT05000411 | Phase 4 | Aug 25, 2021 | Nanjing Medical University |
| NCT04932395 | Phase 4 | Jun 22, 2021 | China Academy of Chinese Medical Sciences, Government of China, Peking University |
| NCT04057547 | Early Phase 1 (Phase 1) | Aug 15, 2019 | China Academy of Chinese Medical Sciences |
| NCT04312477 | Early Phase 1 (Phase 1) | Apr 1, 2019 | China Academy of Chinese Medical Sciences |
| NCT06092736 | Phase 4 | Dec 18, 2018 | Shandong University |
| NCT03270787 | Phase 1/Phase 2 (Phase 2) | Jun 24, 2016 | Tasly Pharmaceuticals, Inc. |
| NCT02524964 | Phase 4 | Dec 1, 2015 | Guangdong Provincial Hospital of Traditional Chinese Medicine |
| NCT02602522 | Early Phase 1 (Phase 1) | Nov 1, 2015 | China Academy of Chinese Medical Sciences, Tsinghua University |
| NCT03591471 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2014 | Chengdu University of Traditional Chinese Medicines, Fudan University, Henan University of Traditional Chinese Medicine, Jiao Tong University, Peking University, Yunnan University of Traditional Chinese Medicine |
| NCT02388984 | Phase 3 | May 1, 2013 | Tasly Pharmaceuticals, Inc. |
| NCT01637675 | Phase 2/Phase 3 (Phase 3) | May 1, 2013 | Capital Medical University, Guangzhou Medical University, Jiangsu Carefree Pharmaceutical Co., Ltd., Jiao Tong University, Nanjing University, Qingdao University, Shantou University, Sun Yat-Sen University, Zhejiang University, Zhengzhou University |
| NCT01761227 | Phase 2 | Sep 1, 2012 | Peking University, Shanghai Hutchison Pharmaceuticals Limited |
| NCT00523146 | Phase 2 | Apr 1, 2007 | Biokey Inc., Jiangsu Kanion Pharmaceutical Co., Ltd |
| NCT01033630 | Phase 2 | Jan 1, 2006 | Chinese University of Hong Kong, City University of Hong Kong |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (28)
28 organizations
Page 1 / 2